文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma".

作者信息

Crochet Gilles, Houot Roch

机构信息

Hematology department, CHU UCL Namur, Yvoir.

Hematology department, Centre Hospitalier Universitaire de Rennes, Rennes.

出版信息

Haematologica. 2025 Mar 1;110(3):808. doi: 10.3324/haematol.2024.286353.

DOI:10.3324/haematol.2024.286353
PMID:39295315
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11873686/
Abstract
摘要

相似文献

[1]
Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma".

Haematologica. 2025-3-1

[2]
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Curr Hematol Malig Rep. 2021-2

[3]
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.

Haematologica. 2024-10-1

[4]
Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.

Br J Haematol. 2023-4

[5]
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

Blood. 2024-8-8

[6]
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.

Front Immunol. 2022

[7]
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.

Br J Haematol. 2022-11

[8]
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Oncologist. 2021-2

[9]
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.

Blood. 2024-7-18

[10]
Update on bi-specific monoclonal antibodies for blood cancers.

Curr Opin Oncol. 2023-9-1

本文引用的文献

[1]
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.

Haematologica. 2024-10-1

[2]
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.

Blood. 2024-7-18

[3]
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

Blood. 2022-9-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索